We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
BLENREP (GlaxoSmithKline Australia Pty Ltd)
Product name
BLENREP
Date registered
Evaluation commenced
Decision date
Approval time
168 (255 working days)
Active ingredients
belantamab mafodotin
Registration type
NCE/NBE
Indication
BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma:
- in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy; and
- in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.